Twitter and its partners are launching a new content product that marries in-person conference news with new digital realities.

January 13, 2022 12:30 PM ESTUpdated 02:22 PM

Marketing

Twitter aims to bring medical conferences — and ad sponsors — from ‘inside 4 walls and 3 days’ to digital future

Beth Snyder Bulik

Senior Editor

Medical conferences’ new hybrid virtual models are changing the news cycle for healthcare professionals. Now Twitter wants to make it easier for physicians to stay …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Twitter aims to bring medical conferences — and ad sponsors — from ‘inside 4 walls and 3 days’ to digital future

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Twit­ter aims to bring med­ical con­fer­ences — and ad spon­sors — from ‘in­side 4 walls and 3 days’ to dig­i­tal fu­ture

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Twitter aims to bring medical conferences — and ad sponsors — from ‘inside 4 walls and 3 days’ to digital future

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena